FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4298008737> ?p ?o ?g. }

• W4298008737 endingPage "e005052" @default.
• W4298008737 startingPage "e005052" @default.
• W4298008737 abstract "We previously reported results from a phase 1 study testing intratumoral recombinant poliovirus, lerapolturev, in 12 melanoma patients. All 12 patients received anti-PD-1 systemic therapy before lerapolturev, and 11 of these 12 patients also received anti-PD-1 after lerapolturev. In preclinical models lerapolturev induces intratumoral innate inflammation that engages antitumor T cells. In the current study, prelerapolturev and postlerapolturev tumor biopsies and blood were evaluated for biomarkers of response.The following analyses were performed on tumor tissue (n=11): (1) flow cytometric assessment of immune cell density, (2) NanoString Digital Spatial profiling of protein and the transcriptome, and (3) bulk RNA sequencing. Immune cell phenotypes and responsiveness to in vitro stimulation, including in vitro lerapolturev challenge, were measured in peripheral blood (n=12).Three patients who received anti-PD-1 therapy within 30 days of lerapolturev have a current median progression-free survival (PFS) of 2.3 years and had higher CD8+T cell infiltrates in prelerapolturev tumor biopsies relative to that of 7 patients with median PFS of 1.6 months and lower CD8+T cell infiltrates in prelerapolturev tumor biopsies. In peripheral blood, four patients with PFS 2.3 years (including three that received anti-PD-1 therapy within 30 days before lerapolturev and had higher pretreatment tumor CD8+T cell infiltrates) had significantly higher effector memory (CD8+, CCR7-, CD45RA-) but lower CD8+PD-1+ and CD4+PD-1+ cells compared with eight patients with median PFS 1.6 months. In addition, pretreatment blood from the four patients with median PFS 2.3 years had more potent antiviral responses to in vitro lerapolturev challenge compared with eight patients with median PFS 1.6 months.An inflamed pretreatment tumor microenvironment, possibly induced by prior anti-PD-1 therapy and a proficient peripheral blood pretreatment innate immune response (antiviral/interferon signaling) to lerapolturev was associated with long term PFS after intratumoral lerapolturev in a small cohort of patients. These findings imply a link between intratumoral T cell inflammation and peripheral immune function.NCT03712358." @default.
• W4298008737 created "2022-10-01" @default.
• W4298008737 creator A5001405213 @default.
• W4298008737 creator A5004814459 @default.
• W4298008737 creator A5007081163 @default.
• W4298008737 creator A5013753246 @default.
• W4298008737 creator A5016582352 @default.
• W4298008737 creator A5019209016 @default.
• W4298008737 creator A5022094836 @default.
• W4298008737 creator A5023554560 @default.
• W4298008737 creator A5045126641 @default.
• W4298008737 creator A5047780979 @default.
• W4298008737 creator A5050528758 @default.
• W4298008737 creator A5051436334 @default.
• W4298008737 creator A5055625321 @default.
• W4298008737 creator A5064761966 @default.
• W4298008737 creator A5075485963 @default.
• W4298008737 date "2022-09-01" @default.
• W4298008737 modified "2023-10-14" @default.
• W4298008737 title "Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma" @default.
• W4298008737 cites W2050216826 @default.
• W4298008737 cites W2060070314 @default.
• W4298008737 cites W2068467835 @default.
• W4298008737 cites W2068691950 @default.
• W4298008737 cites W2109485845 @default.
• W4298008737 cites W2117566531 @default.
• W4298008737 cites W2124427232 @default.
• W4298008737 cites W2154270347 @default.
• W4298008737 cites W2161212381 @default.
• W4298008737 cites W2338576144 @default.
• W4298008737 cites W2539571618 @default.
• W4298008737 cites W2560367415 @default.
• W4298008737 cites W2587048937 @default.
• W4298008737 cites W2592318296 @default.
• W4298008737 cites W2742763599 @default.
• W4298008737 cites W2750781282 @default.
• W4298008737 cites W2754660884 @default.
• W4298008737 cites W2755857262 @default.
• W4298008737 cites W2766762285 @default.
• W4298008737 cites W2767281692 @default.
• W4298008737 cites W2780852610 @default.
• W4298008737 cites W2909486828 @default.
• W4298008737 cites W2909590671 @default.
• W4298008737 cites W2913529349 @default.
• W4298008737 cites W2916647762 @default.
• W4298008737 cites W2930324748 @default.
• W4298008737 cites W2942610007 @default.
• W4298008737 cites W2949315168 @default.
• W4298008737 cites W2960535277 @default.
• W4298008737 cites W2966465234 @default.
• W4298008737 cites W2972816610 @default.
• W4298008737 cites W3014748351 @default.
• W4298008737 cites W3090469545 @default.
• W4298008737 cites W3104746911 @default.
• W4298008737 cites W3132202883 @default.
• W4298008737 cites W3137331444 @default.
• W4298008737 cites W3157263169 @default.
• W4298008737 cites W3180646962 @default.
• W4298008737 cites W3203855951 @default.
• W4298008737 cites W4285388898 @default.
• W4298008737 cites W4292402161 @default.
• W4298008737 cites W88719000 @default.
• W4298008737 doi "https://doi.org/10.1136/jitc-2022-005052" @default.
• W4298008737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36175036" @default.
• W4298008737 hasPublicationYear "2022" @default.
• W4298008737 type Work @default.
• W4298008737 citedByCount "2" @default.
• W4298008737 countsByYear W42980087372022 @default.
• W4298008737 countsByYear W42980087372023 @default.
• W4298008737 crossrefType "journal-article" @default.
• W4298008737 hasAuthorship W4298008737A5001405213 @default.
• W4298008737 hasAuthorship W4298008737A5004814459 @default.
• W4298008737 hasAuthorship W4298008737A5007081163 @default.
• W4298008737 hasAuthorship W4298008737A5013753246 @default.
• W4298008737 hasAuthorship W4298008737A5016582352 @default.
• W4298008737 hasAuthorship W4298008737A5019209016 @default.
• W4298008737 hasAuthorship W4298008737A5022094836 @default.
• W4298008737 hasAuthorship W4298008737A5023554560 @default.
• W4298008737 hasAuthorship W4298008737A5045126641 @default.
• W4298008737 hasAuthorship W4298008737A5047780979 @default.
• W4298008737 hasAuthorship W4298008737A5050528758 @default.
• W4298008737 hasAuthorship W4298008737A5051436334 @default.
• W4298008737 hasAuthorship W4298008737A5055625321 @default.
• W4298008737 hasAuthorship W4298008737A5064761966 @default.
• W4298008737 hasAuthorship W4298008737A5075485963 @default.
• W4298008737 hasBestOaLocation W42980087371 @default.
• W4298008737 hasConcept C126322002 @default.
• W4298008737 hasConcept C142724271 @default.
• W4298008737 hasConcept C154317977 @default.
• W4298008737 hasConcept C167672396 @default.
• W4298008737 hasConcept C202751555 @default.
• W4298008737 hasConcept C203014093 @default.
• W4298008737 hasConcept C2776090121 @default.
• W4298008737 hasConcept C2776107976 @default.
• W4298008737 hasConcept C2777658100 @default.
• W4298008737 hasConcept C2777701055 @default.
• W4298008737 hasConcept C2778326572 @default.
• W4298008737 hasConcept C502942594 @default.

• next